MedTrace Logo

Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes

NCT00497133 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2008-06-04

No results posted yet for this study

Summary

Glucagon-like peptide 1 is known to improve sensitivity of the pancreatic beta-cell. Further it inhibit secretion from the pancreatic alpha-cell by mechanisms not fully understand. With this study we wish to elucidate the potential of GLP-1 to increase the sensitivity of the alpha-cell.

Type 2 diabetic patients and control subjects receive infusions of GLP-1 in increasing doses or saline, alpha- and beta-cell responses are measured in blood-samples. During the study plasma-glucose levels are clamped at fasting levels.

With this study we hope to elucidate the pathophysiology behind defect glucose tolerance in type 2 diabetes mellitus and further more the potential of GLP-1 in treatment of type 2 diabetes mellitus.

Conditions

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • The Danish Diabetes Association

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Jens Juul Holst, Professor, MD,MMSc · University of Copenhagen, Department of Biomedical Sciences

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497133 on ClinicalTrials.gov